EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications

Liu Ma, Mingrong Zhang, Shengdong Gou, Qifu He

Frontiers in Pharmacology · 04.11.2026 · 17

DOI: 10.3389/fphar.2026.1988503 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.11.2026. Verfasst von Liu Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Wuhou District People's Hospital, Chengdu, China. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Group 2 innate lymphoid cells (ILC2s) contribute to type 2 asthma through rapid production of interleukin-5 and interleukin-13, but the inhibitory pathways that restrain pathogenic ILC2 activity remain incompletely defined. Most evidence for programmed cell death protein 1 (PD-1)-mediated inhibition of ILC2s comes from murine models, humanized mice, and stimulated or expanded human cells; cell-resolved expression and functional engagement of PD-1 have not been established in freshly isolated airway ILC2s from well-characterized asthma cohorts. In available experimental systems, PD-1 engagement suppresses ILC2 proliferation and cytokine production, whereas programmed death-ligand 1 (PD-L1) displayed by ILC2s can act outwardly on PD-1-positive CD4-positive T cells. Programmed death-ligand 2 (PD-L2) can inhibit isolated ILC2s through PD-1, but its whole-lung effects also involve dendritic-cell IL-12 regulation and RGMb-dependent respiratory tolerance. Interpretation therefore depends on the ligand-bearing and responding cells, ligand form, tissue compartment, disease stage, and asthma endotype. This review examines cell-intrinsic PD-1 signaling, ligand-specific cellular interactions, immunometabolic regulation, and translational constraints. The current evidence supports preclinical investigation rather than clinical readiness; direct validation in human airway ILC2s, definition of receptor-proximal signaling, and a predictive biomarker are prerequisites for therapeutic development.

Schlagwörter

Stichwörter der Autor:innen

PD-1PD-L1PD-L2asthmagroup 2 innate lymphoid cellsimmune checkpointimmunometabolismtype 2 inflammation

Autor:innen und Institutionen

  • Wuhou District People's Hospital, Chengdu, China.
  • Wuhou District Health Hospital for Woman & Children, Chengdu, China.

Zitieren

APA

Ma, L., Zhang, M., Gou, S., & He, Q. (2026). PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1988503

Vancouver

Ma L, Zhang M, Gou S, He Q. PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1988503

BibTeX
@article{Ma2026,
  author = {Ma, Liu and Zhang, Mingrong and Gou, Shengdong and He, Qifu},
  title = {PD-1 and its ligands in ILC2-mediated airway inflammation in asthma: context-dependent mechanisms and therapeutic implications},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1988503}
}
Kostenlos starten →